New and emerging drugs in type 2 diabetes.
- Author:
Ie Byung PARK
1
Author Information
1. Department of Endocrinology, Gachon University of Science and Medicine, Gil Medical Center, Incheon, Korea.
- Publication Type:Review
- Keywords:
Incretin;
Exenatide;
DPP-IV inhibitor;
Pramlintide;
Rimonabant;
Inhaled insulin
- MeSH:
Dipeptidyl-Peptidase IV Inhibitors;
Glucagon-Like Peptide 1;
Humans;
Incretins;
Insulin;
Islet Amyloid Polypeptide;
Peroxisomes
- From:Korean Journal of Medicine
2007;72(5):446-450
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. Several new emerging drugs and drug classes for the management of diabetes are under development, including the incretin mimetic agents (exenatide, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide 1 analogues), the amylin analogue pramlintide, the cannabinoid-1 receptor antagonist rimonabant, the mixed peroxisome proliferator-activated receptor agonists muraglitazar and the inhaled insulin preparation Exubera. New drugs and technologic advances being made available will help achieve the goals of treating patients with diabetes to all the appropriate metabolic targets. Longer term studies will help providers weigh the benefits, adverse effects, cost, and unknown long-term risks of these medications.
